322 related articles for article (PubMed ID: 29542120)
21. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
[TBL] [Abstract][Full Text] [Related]
22. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
[TBL] [Abstract][Full Text] [Related]
23. Altered vascular endothelial growth factor expression during GnRH antagonist protocol in women of reproductive age with normal baseline hormone profiles.
Koo YA; Lee B; Park HJ; Choi J; Lee E; Choi D
Fertil Steril; 2009 Mar; 91(3):744-8. PubMed ID: 18321491
[TBL] [Abstract][Full Text] [Related]
24. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.
Hum Reprod; 1998 Nov; 13(11):3023-31. PubMed ID: 9853849
[TBL] [Abstract][Full Text] [Related]
25. The comparison of microdose flare-up and multiple dose antagonist protocols based on hCG day estradiol (E2), progesterone (P) and P/E2 ratio among poor responder patients in ICSI-ET cycles.
Cicek MN; Kahyaoglu I; Kahyaoglu S
Eur Rev Med Pharmacol Sci; 2015 Feb; 19(4):539-44. PubMed ID: 25753867
[TBL] [Abstract][Full Text] [Related]
26. Gonadotropin releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome.
Ozelci R; Dilbaz S; Dilbaz B; Cırık DA; Yılmaz S; Tekin OM
Taiwan J Obstet Gynecol; 2019 Mar; 58(2):234-238. PubMed ID: 30910145
[TBL] [Abstract][Full Text] [Related]
27. In vitro fertilization outcomes in patients experiencing a premature rise in luteinizing hormone during a gonadotropin-releasing hormone antagonist cycle.
Kummer NE; Weitzman VN; Benadiva CA; Schmidt DW; Engmann LL; Nulsen JC
Fertil Steril; 2011 Jun; 95(8):2592-4. PubMed ID: 21292260
[TBL] [Abstract][Full Text] [Related]
28. GnRH antagonist versus follicular-phase single-dose GnRH agonist protocol in patients of normal ovarian responses during controlled ovarian stimulation.
Geng Y; Xun Y; Hu S; Lai Q; Jin L
Gynecol Endocrinol; 2019 Apr; 35(4):309-313. PubMed ID: 30430883
[TBL] [Abstract][Full Text] [Related]
29. Influence of Different Gonadotropin-releasing Hormone Agonist Administration Methods on Pregnancy Outcomes of Patients Undergoing In-vitro Fertilization-embryo Transfer.
Wu L; Ren XL; Chen W; Huang B; Zhou YF; Jin L
Curr Med Sci; 2019 Jun; 39(3):437-441. PubMed ID: 31209816
[TBL] [Abstract][Full Text] [Related]
30. Preliminary report on the effect of a lower dose of gonadotropin-releasing hormone antagonist (cetrorelix) on ovarian hyperstimulation in lower-weight Asian women.
Chang YL; Hsieh YY; Tsai HD
Taiwan J Obstet Gynecol; 2006 Dec; 45(4):317-20. PubMed ID: 17175489
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the GnRH agonist and antagonist protocol on the same patients in assisted reproduction during controlled ovarian stimulation cycles.
Lai Q; Zhang H; Zhu G; Li Y; Jin L; He L; Zhang Z; Yang P; Yu Q; Zhang S; Xu JF; Wang CY
Int J Clin Exp Pathol; 2013; 6(9):1903-10. PubMed ID: 24040457
[TBL] [Abstract][Full Text] [Related]
32. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation.
Albano C; Smitz J; Camus M; Riethmüller-Winzen H; Van Steirteghem A; Devroey P
Fertil Steril; 1997 May; 67(5):917-22. PubMed ID: 9130900
[TBL] [Abstract][Full Text] [Related]
33. A Premature Rise of Luteinizing Hormone Is Associated With a Reduced Cumulative Live Birth Rate in Patients ≥37 Years Old Undergoing GnRH Antagonist
Gao F; Wang Y; Wu D; Fu M; Zhang Q; Ren Y; Yang Z; Shen H; Han H
Front Endocrinol (Lausanne); 2021; 12():722655. PubMed ID: 34925227
[TBL] [Abstract][Full Text] [Related]
34. What are the best predictors for successful GnRH antagonist protocol in in vitro fertilization (IVF) treatment?
Samara N; Reis D; Danielli Miller N; Ghetler Y; Berkovitz A; Miller M; Gonen O; Shulman A; Wiser A
Gynecol Endocrinol; 2015; 31(11):877-9. PubMed ID: 26416777
[TBL] [Abstract][Full Text] [Related]
35. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
[TBL] [Abstract][Full Text] [Related]
36. GnRH antagonists in ovarian stimulation for IVF.
Tarlatzis BC; Fauser BC; Kolibianakis EM; Diedrich K; Rombauts L; Devroey P
Hum Reprod Update; 2006; 12(4):333-40. PubMed ID: 16567347
[TBL] [Abstract][Full Text] [Related]
37. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
38. Characteristics of progesterone changes in women with subtle progesterone rise in recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonist cycle.
Seow KM; Lin YH; Hsieh BC; Huang LW; Huang SC; Chen CY; Chen PH; Tzeng CR; Hwang JL
Gynecol Obstet Invest; 2010; 70(1):64-8. PubMed ID: 20203521
[TBL] [Abstract][Full Text] [Related]
39. Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration.
Hugues JN; Massé-Laroche E; Reboul-Marty J; Boîko O; Meynant C; Cédrin-Durnerin I
Fertil Steril; 2011 Sep; 96(3):600-4. PubMed ID: 21880277
[TBL] [Abstract][Full Text] [Related]
40. Effect of progesterone/estradiol ratio on pregnancy outcome of patients with high trigger-day progesterone levels undergoing gonadotropin-releasing hormone antagonist intracytoplasmic sperm injection cycles: a retrospective cohort study.
Golbasi H; Ince O; Golbasi C; Ozer M; Demir M; Yilmaz B
J Obstet Gynaecol; 2019 Feb; 39(2):157-163. PubMed ID: 30280612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
